The 2015 screening hold that led to 17 SOC/placebo patients being kept of the trial and a reduced powering as well as Fraunhofer’s statement in their 2015 annual report that enrollment occurred to the point statistically necessary being backed by peer review in JAMA Oncology while NWBO spent big money getting manufacturing up to speed to support their ability to have a verifiably realistic answer to their ramp up plan is all the verification anyone really needed. This is just the cherry on top and if you are waiting for further verification then you will need to wait at the back of the line where those who are still not convinced can exit first or pay more to enter; ). Best wishes.
Market Data 
Markets 
